A 20% relative risk reduction in MACE, including myocardial infarction, stroke, and cardiovascular death and a 30% relative risk reduction in hospitalizations for HF ( The VERTIS trial, involving 8246 patients with T2DM, compared ertugliflozin 5 mg or 15 mg daily to placebo for 3.5 years
But what many people may not realize is that this powerful compound also has a distinctive taste and smell that can be quite off-putting
#VCT220 #GLP1 #MedicinalChemistry #Obesity #ClinicalPipeline #DrugDiscovery #ChinaBiotech #CX11 To view or add a comment, sign in 8,052 followers
Stable gastric pentadecapeptide BPC 157 and intestinal anastomosis therapy in rats
Therapeutic trimming, specialized shoeing, boots, pads, or impression materials may be used depending on the horse's needs